Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab with Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
NCT00742560Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2008
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of elotuzumab in multiple myeloma (MM) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Objective Response Rate up to 101 months. Started Aug 2008; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00742560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742560.